# Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer

> **NCT03982004** · PHASE1 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 1 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DEVICE:** Epicutaneous cryoimmunotherapy
- **DRUG:** Topical imiquimod
- **DRUG:** Pembrolizumab
- **OTHER:** Dermatologic Quality of Life Index
- **OTHER:** Functional Assessment of Cancer Therapy
- **DRUG:** Intra-lesional GM-CSF
- **DEVICE:** Cry-AC
- **PROCEDURE:** Cutaneous tumor biopsy
- **PROCEDURE:** Peripheral blood draw for research

## Key facts

- **NCT ID:** NCT03982004
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-14
- **Primary completion:** 2021-03-03
- **Final completion:** 2021-03-03
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Sponsor decision.
- **Last updated:** 2021-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03982004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03982004, "Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03982004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*